Reaction

Implant Site Erythema reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 936 reports · 3 co-occurring drugs

As of the last recalculation, Implant Site Erythema appears in 936 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is ETONOGESTREL (PRR 984.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Etonogestrel	649	984.0	997.6
Bupivacaine	8	19.2	19.2
Testosterone	15	14.5	14.5

Related reactions

Drug Ineffective
Off Label Use
Death
Nausea
Fatigue

Data source: openFDA FAERS. See the OpenPV methodology and limitations.